Saturday 17 October 2026
Export LGVN’s income statement to Excel — free account
Longeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.
1.39
0.11
−7.33%
Follow LGVN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
3 | 5 | 2 | 3 | 3 | 5 | — | — | — |
P/S ratio |
7.42 | 6.81 | 40.46 | 57.83 | 174.86 | 21.09 | 21.09 | 21.09 | — |
Altman Z-Score |
(24.10) | (4.58) | (12.02) | 1.20 | 23.95 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(55.12) | (7.69) | (32.25) | (5.08) | 6.32 | (13.36) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
(3.83) | (1.65) | (3.82) | (0.45) | (7.22) | (3.16) | — | — | — |
P/Operating CF |
(1.68) | (4.83) | (7.18) | (30.62) | (178.27) | (235.07) | (235.07) | (235.07) | — |
P/B ratio |
1.57 | 0.74 | 4.26 | 3.45 | 6.10 | 60.66 | 60.66 | 60.66 | — |
Price to Tangible BV |
2.62 | 0.84 | 6.44 | 3.91 | 6.50 | 289.53 | 289.53 | 289.53 | — |
EV/Sales |
3.68 | (0.89) | 34.94 | 43.42 | 150.02 | 21.02 | 21.02 | 21.02 | — |
EV/EBITDA |
0.00 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(0.24) | 0.15 | (1.30) | (3.80) | (20.33) | (50.06) | (50.06) | (50.06) | — |
EV/FCF |
(0.23) | 0.14 | (1.26) | (3.58) | (17.95) | (45.07) | (45.07) | (45.07) | — |
Quick Ratio |
1.17 | 7.48 | 1.41 | 4.08 | 12.96 | 0.32 | 0.93 | 2.16 | — |
Current Ratio |
1.33 | 7.60 | 1.50 | 4.17 | 13.07 | 0.48 | 0.95 | 2.24 | — |
Net Debt/EBITDA |
0.20 | 1.18 | 0.19 | 1.03 | 1.96 | 0.12 | (1.02) | 0.72 | — |
Debt/Assets |
1.65% | 3.22% | 11.99% | 7.45% | 6.09% | 4.87% | 39.10% | 0.00% | 0.00% |
Debt/Equity |
0.03 | 0.04 | 0.21 | 0.10 | 0.07 | 0.23 | 0.93 | 0.00 | — |
Asset Turnover |
0.07 | 0.13 | 0.04 | 0.03 | 0.05 | 0.57 | 0.53 | 0.41 | — |
Operating CF/Net income |
0.82 | 0.56 | 0.86 | 0.74 | 0.57 | 0.64 | 0.81 | 0.82 | — |
Capex/Depreciation |
(0.49) | (1.04) | (0.73) | (0.96) | (1.34) | (0.33) | (0.16) | 0.00 | — |
Interest Coverage |
— | — | — | — | 4,364.00 | (539.71) | (14,990.50) | (534.50) | — |
| (164.75%) | (172.02%) | (163.05%) | (65.00%) | (86.50%) | (116.24%) | (52.58%) | (112.56%) | — | |
| (126.77%) | (130.85%) | (112.49%) | (53.68%) | (65.55%) | (37.54%) | (28.05%) | (120.45%) | — | |
ROIC |
(1,230.29%) | (296.82%) | (464.75%) | (390.74%) | (217.55%) | (148.41%) | (27.89%) | 0.00% | — |
Return on Tangible Assets |
(709.50%) | (126.33%) | (494.90%) | (102.59%) | (47.70%) | (230.26%) | (72.68%) | (89.73%) | — |
Average Days of Receivables |
31.66 | 12.82 | 57.14 | 65.11 | 15.37 | 27.23 | 29.22 | 0.00 | — |
Research and Development Expense of Revenue |
1,004.25% | 340.18% | 1,278.70% | 766.78% | 543.03% | 47.50% | 31.77% | 181.55% | — |
Selling, General and Administrative Expense of Revenue |
1,004.92% | 429.31% | 1,718.48% | 750.41% | 838.74% | 52.05% | 52.49% | 148.28% | — |
Intangible Assets out of Total Assets |
0.22 | 0.09 | 0.19 | 0.09 | 0.05 | 0.17 | 0.14 | 0.13 | 0.00 |
Share Based Compensation of Revenue |
139.87% | 97.32% | 286.60% | 177.33% | 493.34% | 0.69% | 2.43% | 0.00% | — |
Graham Net Nets |
0.10 | 0.98 | 0.02 | 0.19 | 0.13 | (0.05) | (0.05) | (0.05) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(252.96%) | (174.24%) | (77.27%) | (26.71%) | (7.37%) | (3.14%) | (3.14%) | (3.14%) | — |
Free Cash Flow Yield |
(216.33%) | (91.27%) | (68.67%) | (20.98%) | (4.78%) | (2.21%) | (2.21%) | (2.21%) | — |
Revenue per Share |
0.68 | 2.54 | 3.26 | 5.83 | 6.90 | 35.14 | 0.30 | 0.11 | — |
Operating CF per Share |
(10.61) | (14.74) | (87.45) | (66.61) | (50.93) | (14.76) | (0.13) | (0.27) | — |
Capex per Share |
(0.34) | (1.05) | (3.19) | (4.08) | (6.47) | (1.63) | (0.01) | 0.00 | — |
Free Cash Flow per Share |
(10.95) | (15.79) | (90.64) | (70.70) | (57.40) | (16.39) | (0.13) | (0.27) | — |
Cash per Share |
2.65 | 20.44 | 24.67 | 93.74 | 185.22 | 5.09 | 0.10 | 0.21 | — |
Shareholders Equity per Share |
3.23 | 23.26 | 31.02 | 97.77 | 197.95 | 12.22 | 0.23 | 0.36 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.23 | 23.26 | 31.02 | 97.77 | 197.95 | 12.22 | 0.23 | 0.36 | — |
Free Cash Flow |
(19.24) | (14.86) | (19.70) | (14.82) | (10.86) | (2.62) | (2.52) | (5.18) | — |
Working Capital |
1.36 | 17.04 | 1.96 | 15.41 | 32.67 | (1.98) | (0.12) | 2.30 | — |
Capital Expenditures |
(0.59) | (0.99) | (0.69) | (0.86) | (1.22) | (0.26) | (0.13) | (0.21) | — |
Net Current Asset Value |
0.87 | 15.95 | 0.51 | 13.37 | 30.07 | (5.43) | (3.77) | 0.46 | — |
EV/EBIT |
0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.50 | 0.41 | 0.98 | 0.70 | 0.94 | 0.05 | 0.02 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.67 | 0.39 | 0.37 | 0.30 | 0.30 | 0.22 | 0.18 | 0.16 | — |
Cash ROIC |
(183.15%) | (35.43%) | (145.36%) | (35.13%) | (14.46%) | (81.45%) | (24.08%) | (47.74%) | — |
Accounts Receivable Turnover |
12.76 | 24.53 | 4.31 | 8.95 | 5.50 | 12.92 | 12.93 | 0.00 | — |
Accounts Payable Turnover |
1.52 | 1.38 | 0.41 | 0.61 | 0.64 | 2.77 | 3.29 | 1.23 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
389.89 | 71.13 | 477.19 | 881.54 | 328.81 | 152.60 | 108.47 | 302.57 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
0.09 | 0.10 | 0.16 | 0.14 | 0.24 | 0.44 | 0.44 | — | — |
Average Payables |
0.26 | 0.37 | 1.19 | 1.20 | 1.12 | 1.37 | 1.18 | 1.18 | — |
Average Assets |
17.91 | 18.82 | 19.75 | 35.09 | 26.00 | 9.91 | 10.55 | 5.26 | — |
Average Common Equity |
13.78 | 14.31 | 13.62 | 28.98 | 19.71 | 3.20 | 5.63 | 5.63 | — |
Columns are period end dates